Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes

 Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes

Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes

Shots:

  • In terms of the agreement, lilly will commercialize the system, which is currently in development & will include an insulin pump developed & manufactured by ypsomed
  • Ypsomed’s insulin pump has been marketed in europe since 2016, available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump, along with CGM & automated insulin delivery technology, in the US & europe also this pump will use pre-filled insulin cartridges for Lilly’s rapid-acting insulins
  • Ypsomed plans to submit a version of the mylife ypsopump for clearance to the US FDA for use in automated insulin delivery in 2022, if cleared, lilly will have exclusive rights to commercialize the pump in the US

Click here ­to­ read full press release/ article | Ref: Lilly | Image: Lilly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post